



臺中榮民總醫院
Taichung Veterans General Hospital

Prone position ventilation – from theory to practice

July 3, 2022

趙文震 醫師 MD, PhD.

臺中榮總重症醫學部

俯臥通氣治療健保異動規定(111.04.01)

1. 申報代碼47104B，支付點數**5,114**點/每一療程。

2. 每一療程:係指仰臥→俯臥→仰臥

3. 適應症：

(1)成人(19歲以上)，入住加護病房且插管使用呼吸器之急性呼吸窘迫症候群病人(J80)，並同時符合下列各項條件

- A. 氧合指數(PaO₂/FiO₂ratio)≤150
- B. 七日內急性發作
- C. 沒有心因性肺水腫的證據
- D. CXR顯示兩側肺野浸潤

(2)兒童(未滿19歲)，入住加護病房且插管使用呼吸器，並同時符合下列各項條件之一者

- A. 氧合指數(PaO₂/FiO₂ratio)≤150
- B. OI>16
- C. OSI>12.3

3. 禁忌症：心胸及腹腔主要手術、脊椎與骨盆不穩定、懷孕第二及第三期、頭部外傷、腦壓或眼壓過高之病人、正在發作之癲癇患者。

4. 限內科、外科、麻醉科、兒科、急診醫學科、神經科、神經外科專科醫師執行


5. 不得同時申報47045C。

Outline

1. Prone ventilation till 2013 [PROSEVA]
2. Prone ventilation evidence ~2014-2019
[LUNG-SAFE, TSIRC, APRONET]
3. Prone positioning in COVID-19 era
4. Prone ventilation on ECMO

Prone Positioning in Severe Acute Respiratory Distress Syndrome

PF ratio <150



No. at Risk					
Prone group	237	202	191	186	182
Supine group	229	163	150	139	136

12-24 hour stabilization period of supine ventilation Then initiating prone ventilation **early (up to 36 hours)**

Mean duration of time in the prone position was **17 hours/day** with an average of **4 sessions**.

Protective ventilation strategies are typically **concurrently** employed.

NMBAs in prone and supine ventilation (**91% vs. 82%**)



PROSEVA Study Group


Claude Guérin et al. PMID: 23688302
N Engl J Med. 2013 Jun 6;368(23):2159-68.

Effect of prone positioning during mechanical ventilation on mortality among patients with acute respiratory distress syndrome : a systematic review and meta-analysis

- The fundamental role of protective lung ventilation


Protective lung ventilation (+)

Protective lung ventilation (-)



Sachin Sud et al. PMID: 24863923
CMAJ. 2014 Jul 8;186(10):E381-90.

Prone positioning **reduces** mortality from acute respiratory distress syndrome in the low tidal volume era: a meta-analysis



**Jeremy R. Beitler et al. PMID: 24435203
Intensive Care Med. 2014 Mar; 40(3): 332–341.**

Mechanisms for prone response

Mechanisms for prone response

© 2021 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Proposed mechanisms for prone response


	Physiologic effect	Clinical result
Improved configuration between lung and thorax		
Heart is dependent	More homogeneous Ppl gradient in ventrodorsal and cephalocaudal planes	Improved ventilation distribution
Smaller volume of dependent lung		Increased FRC (↓ shunt)
Abdomen is unsupported*		
Secretion mobilization	Improved bronchial drainage	Improved ventilation
Improved aerosol delivery	Improved effect of aerosolized meds	Improved ventilation
More homogeneous perfusion	Less dependent perfusion	Improved V/Q matching (↓ shunt)

- More homogenous Ppleural and perfusion
- Improved bronchial drainage

V/Q in supine and prone ventilation


Ventilation

Perfusion




- 1. Gravity
- 2. Shape of chest wall
- 3. Heart and diaphragm

Supine position		PTP	Blood flow
		+++	



SUPINE




PRONE

Prone positioning

Effect and duration on P/F ratio

Course of $\text{PaO}_2/\text{FiO}_2$ during four consecutive 24-hour periods of prone positioning



Fridrich, P, Krafft, P, Hochleuthner, H, et al., Anesth Analg 1996; 83:1206.

Prone positioning evidence ~2014-2019
(Taiwan 2016 influenza epidemic)

Epidemic: 2016-Spring influenza in Taiwan

已無葉克膜救人 流感延燒 衛福部擺爛不調度
壯男早上騎車 下午加護病房 流感發病快又猛 已奪84命

2016年03月04日

G+1 33



流感疫情發燒
因急診待床患者
暴增，只能暫時將部分
病床安排在電梯口。詹
智淵攝

【綜合報導】流感疫情大爆炸，急重症病患發病又快又猛，救命的葉克膜卻告急，台大、馬偕、中國醫藥大學附設醫院、彰化基督教醫院、高雄長庚等醫院的葉克膜體外循環器已全數滿機，陷入零空機困境，第一線醫師心急如焚，表示「已沒有武器（指葉克膜）可救人」，要求衛福部統籌調度。但衛福部無視人命關天，昨仍被動地說，現無法得知哪些醫院葉克膜不足，呼籲醫院有需要可告知衛福部介入協助。民眾則痛罵衛福部「根本是草菅人命」！

- 已無ECMO救人？
- 擺爛不調度？
-


2016-03-04

Rapid recovery under early treatment



Early tamiflu, **early** protective ventilation strategy,
early prone position, **early** dry-lung strategy

Influenza A /c severe ARDS



Day 1
FiO2 70%, P/F ratio: 98
PEEP: 16, TV: 300 (IBW: 52)
Tamiflu, EGDT,
protective ventilation strategy

Prone →


Day 2
FiO2 45%, P/F ratio: 155
PEEP: 16, TV: 300 (IBW: 52)
Toward dry-lung strategy

Day 6
FiO2 35%, **extubation** with
HFNC (High-flow nasal cannula)

Case report → Case series → Nationwide study

Case report

Influenza A /c severe ARDS



Day 1
FiO2 70%, P/F ratio: 98
PEEP: 16, TV: 300 (IBW: 52)
Tamiflu, EGD, protective ventilation strategy

→ Prone →


Day 2
FiO2 45%, P/F ratio: 155
PEEP: 16, TV: 300 (IBW: 52)
Toward dry-lung strategy



Day 6
FiO2 35%, extubation with HFNC (High-flow nasal cannula)

Case series

Prone ventilation severe ARDS (n=12)



Taiwan Severe Influenza Research Consortium (TSIRC)

2016/03/12



Taiwan Severe Influenza Research Consortium (TSIRC)



1. **First tidal volume** greater than 8 mL/kg is associated with increased mortality in complicated influenza infection with acute respiratory distress syndrome.

Chan MC et al. Taiwan Severe Influenza Research Consortium **TSIRC (Taiwan Severe Influenza Research Consortium)**.
J Formos Med Assoc. 2018. PMID: 30041997

2. Association of day 4 cumulative **fluid balance** with mortality in critically ill patients with influenza: A multicenter retrospective cohort study in Taiwan.

Chao WC et al. **TSIRC (Taiwan Severe Influenza Research Consortium)**.
PLoS One. 2018 Jan 9;13(1):e0190952. PMID: 29315320

3. Predictors of survival in patients with influenza pneumonia-related severe acute respiratory distress syndrome treated with **prone positioning**.

Kao KC et al. **TSIRC (Taiwan Severe Influenza Research Consortium)**.
Ann Intensive Care. 2018 Sep 24;8(1):94. doi: 10.1186/s13613-018-0440-4

4. **Impact of corticosteroid** treatment on clinical outcomes of influenza-associated ARDS: a nationwide multicenter study.

Tsai MJ et al. Taiwan Severe Influenza Research Consortium (TSIRC) Investigators.
Ann Intensive Care. 2020 Feb 27;10(1):26.

5. Risk factor analysis of **nosocomial lower respiratory tract infection** in influenza-related acute respiratory distress syndrome.

Chen WC et al. **TSIRC (Taiwan Severe Influenza Research Consortium)**.
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620942417.


6. Using a **machine learning approach** to predict mortality in critically ill influenza patients: a cross-sectional retrospective multicentre study in Taiwan.

Hu CA et al. **TSIRC (Taiwan Severe Influenza Research Consortium)**.
BMJ Open. 2020 Feb 25;10(2):e033898.

7. Comparison of **prone positioning** and extracorporeal membrane oxygenation in acute respiratory distress syndrome: A multicenter cohort study and propensity-matched analysis

Chang KW et al. **TSIRC (Taiwan Severe Influenza Research Consortium)**.
J Formos Med Assoc. 2021 Oct 16;S0929-6646(21)00479-4

Flow chart of enrollment of participants



316 virology-proven cases in 2016-epidemic

263 ARDS
Severe ARDS (59.3%, 156/263)

Mortality 23.1% (61/263)

^a Virology proofs include RIDT, RT-PCR, and viral culture.

Abbreviations: ICU: Intensive care unit; RIDT: Rapid influenza diagnostic test; ARDS: Acute respiratory distress syndrome (Berlin definition)

Figure 1. Flow chart of subjects enrollment.

Table 1. Characteristics of the 263 subjects with influenza-related ARDS categorized by 30-day mortality

	All (N=263)	Survivor (N=202)	Non-survivor (N=61)	P value
Basic data				
Age (years)	59.8±14.6	59.2±14.7	61.7±14.4	0.25
Male %	166 (63.1%)	126 (62.4%)	40 (65.6%)	0.76
.....				
Subtypes of influenza				
Type A (%)	205 (77.9%)	159 (78.7%)	46 (75.4%)	0.69
Type B (%)	23 (8.7%)	16 (7.9%)	7 (11.5%)	
Positive, unknown subtype (%)	35 (13.3%)	27 (13.4%)	8 (13.1%)	
Laboratory data				
.....				
Serum C-reactive protein (mg/dL)	15.3±10.2	14.5±9.9	17.8±11.0	0.03
Serum lactate level (mg/dL)	29.6±36.6	23.8±23.4	47.4±58.1	<0.01
Severity scores				
Pneumonia Severity Index	119.9±46	112±42.3	145.5±48.7	<0.01
APACHE II	23.6±8.6	22.1±8	28.9±8.4	<0.01
SOFA score				
Day-1	10.6±4	9.9±3.8	12.8±4	<0.01
Day-3	9.9±4.4	9±4.1	13±4.1	<0.01
Day-7	8.4±4.3	7.5±3.7	12.1±4.8	<0.01
PaO ₂ /FiO ₂	106.8±62.2	112.3±65.2	88.5±47.5	<0.01
Management and outcomes				
ICU-wait ^c (days)	0.9±1.8	0.9±1.7	1.1±2.2	0.33
Prone-ventilation (%)	65 (23.2%)	45 (21.8%)	20 (27.9%)	0.39
ECMO (%)	50 (19%)	30 (14.9%)	20 (32.8%)	<0.01
Renal replacement therapy ^d (%)	31 (11.8%)	15 (7.4%)	16 (26.2%)	<0.01

Prone-positioning (23.2%)

Predictors of survival in patients with influenza pneumonia-related severe acute respiratory distress syndrome treated with prone positioning.




Table 3 Cox regression analysis of clinical variables associated with 60-day mortality in influenza pneumonia-related ARDS with prone positioning

Clinical variables	Univariate		Multivariate	
	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value
APACHE II score	1.089 (1.035–1.147)	0.001*	1.042 (0.982–1.106)	0.178
PSI	1.015 (1.005–1.026)	0.003*	1.020 (1.009–1.032)	<0.001
Renal replacement therapy	5.355 (2.159–13.281)	0.000*	6.248 (2.245–17.389)	<0.001
Δ Peak airway pressure (cm H ₂ O)	1.143 (1.019–1.282)	0.022*	0.996 (0.822–1.208)	0.969
<u>Δ Dynamic driving pressure (cm H₂O)</u>	<u>1.147 (1.008–1.305)</u>	<u>0.037*</u>	<u>1.372 (1.095–1.718)</u>	<u>0.006</u>
Δ Dynamic compliance (ml/cm H ₂ O)	0.925 (0.871–0.983)	0.011*	0.941 (0.872–1.015)	0.117

ARDS acute respiratory distress syndrome, CI confidence interval, APACHE II Acute Physical and Chronic Health Evaluation, PSI pneumonia severity index, Δ difference between before and after prone positioning 1 day

*p < 0.05

- **65 patients receiving prone ventilation:** Survivors (n=45); Non-survivors (n=20).
- An increase in dynamic driving pressure were associated with 60-day mortality in patients with influenza pneumonia-related ARDS receiving prone positioning


Kuo-Chin Kao, et al. PMID: 30251181
Ann Intensive Care. 2018 Sep 24;8(1):94.

知易行難

ARDS-Protective ventilation

ARDS-Prone positioning

Flow chart of enrollment of participants



316 virology-proven cases in 2016-epidemic

263 ARDS
Severe ARDS (59.3%, 156/263)

Mortality 23.1% (61/263)

^a Virology proofs include RIDT, RT-PCR, and viral culture.

Abbreviations: ICU: Intensive care unit; RIDT: Rapid influenza diagnostic test; ARDS: Acute respiratory distress syndrome (Berlin definition)


Figure 1. Flow chart of subjects enrollment.

Table 2. Respiratory parameters of subjects with influenza-related **ARDS** categorized by 30-day mortality



	All (N=263)	Survivor (N=202)	Non-survivor (N=61)	P value
Day-intubation (N=222)				
FiO ₂ (%)	80.7±22	78.1±22.7	89.3±16.8	<0.01
PEEP	10.6±3.8	10.9±4	9.6±3	0.01
V_T/PBW	8.5±2	8.2±1.9	9.3±2.2	<0.01
P _{peak}	29.3±4.9	29.2±4.9	29.7±4.9	0.52
Day 1 (N=233)				
FiO ₂ (%)	63.4±22.5	59.4±21.2	77.2±21.4	<0.01
PEEP	11.7±3.7	11.6±3.7	12.1±3.6	0.38
V_T/PBW	8.3±2	8.3±2	8.1±2.1	0.44
P _{peak}	28.5±4.7	28.3±4.8	29.5±4	0.10
Day 2 (N=233)				
FiO ₂ (%)	54.5±20.2	51.7±18.5	65.5±22.8	<0.01
PEEP	11.5±3.7	11.3±3.8	12.6±3.3	0.03
V_T/PBW	8.1±2	8.2±2	7.7±1.9	0.09
P _{peak}	28±5.2	27.5±5.3	29.8±4.1	0.01

Early low tidal volume ventilation is associated with 30-day mortality



A surprisingly **low proportion** of implementation of **low tidal volume ventilation**




$$V_T/PBW \leq 8$$

42.6%


51.2%

54.0%


Day-intubation TV/PBW




Day-1 TV/PBW



Day-2 TV/PBW



The real-world application of the early low tidal volume ventilation



Protective ventilation strategy in ARDS



**Real-world practice in countries
other than Taiwan**


Epidemiology, Patterns of Care, and Mortality for Patients With **Acute Respiratory Distress Syndrome** in Intensive Care Units in **50 Countries**

- **4 consecutive weeks** in the winter of 2014 in a convenience sample of 459 ICUs from **50 countries** across 5 continents.
- Of **29,144** patients admitted to participating ICUs, **3022 (10.4%) fulfilled ARDS criteria.**
- Mild, moderate and severe ARDS was 30.0%, 46.6% and 23.4%, respectively.

LUNG SAFE Investigators

*Giacomo Bellani et al. PMID: 26903337
JAMA. 2016 Feb 23;315(8):788-800*

Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the **LUNG SAFE** study



Intensive Care Med. 2016 Dec;42(12):1865-1876

Real-world poor adherence for LTVV



➤ Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries

✓ **LUNG SAFE study** (50 countries)

✓ **Less than two-thirds** of patients with ARDS received a TV/PBW \leq 8 mL/kg

Giacomo Bellani et al. JAMA. 2016 Feb 23;315(8):788-800.

➤ Low Tidal Volume Ventilation Use in Acute Respiratory Distress Syndrome

✓ **Using electronic health records (EHRs)** to assess the real-world practical compliance of LTVV in four American hospitals

✓ **Only 54%** of ARDS patients received a TV/PBW \leq 8 mL/kg

Weiss CH et al. Crit Care Med 2016; 44:1515-1522

Real-world application of prone position

The rate of use of prone position has been found as low as in **severe ARDS** patients in the recent large prospective epidemiologic **Lung safe study**.

LUNG SAFE Investigators


*Giacomo Bellani et al. PMID: 26903337
JAMA. 2016 Feb 23;315(8):788-800*

Hallmark studies of prone positioning

- PROSEVA in 2013
- LUNG-SAFE in 2014
- TSIRC in 2016
- **APRONET in 2017**

A prospective **international** observational prevalence study on prone positioning of ARDS patients

- Prospective international **1-day prevalence study** performed four times in April, July, and October 2016 and January 2017.
- **6723 patients** were screened in 141 ICUs from 20 countries
- **735 had ARDS** and were analyzed.
- **101 ARDS patients** had at least one session of PP (13.7%)




APRONET (ARDS Prone Position Network) study



*Claude Guérin et al. PMID: 29218379
Intensive Care Med . 2018 Jan;44(1):22-37.*

A prospective **international** observational prevalence study on prone positioning of ARDS patients



- The rate of PP use was 5.9% (11/187), 10.3% (41/399) and 32.9% (49/149) in mild, moderate and severe ARDS,

APRONET (ARDS Prone Position Network) study



Claude Guérin et al. PMID: 29218379
Intensive Care Med . 2018 Jan;44(1):22-37.

A prospective **international** observational prevalence study on prone positioning of ARDS patients

- **Duration**

→ 18 (16-23) hours.

- **Efficacy of 1st prone**

→ **PaO₂/FIO₂** increased from 101 (76-136) to 171 (118-220) mmHg;

→ **Driving pressure** decreased from 14 [11-17] to 13 [10-16] cmH₂O

→ **Pplat** decreased from 26 [23-29] to 25 [23-28] cmH₂O (P = 0.04).



APRONET (ARDS Prone Position Network) study

*Claude Guérin et al. PMID: 29218379
Intensive Care Med . 2018 Jan;44(1):22-37.*

A prospective **international** **observational prevalence** study on prone positioning of ARDS patients

- Reason for not using PP

→ (64.3%) was that hypoxemia was **not considered sufficiently severe**.

- Complications

→ were reported in 12 patients (11.9%)

→ **Pressure sores** in five, **hypoxemia** in two, endotracheal tube-related in two, ocular in two, and a transient increase in intracranial pressure in one).



APRONET (ARDS Prone Position Network) study

*Claude Guérin et al. PMID: 29218379
Intensive Care Med . 2018 Jan;44(1):22-37.*

Prone position

1. Contraindications

2. Complications

Prone positioning

Absolute contraindication

1. Shock (hemodynamic cannot be stabilized)
2. Life-threatening arrhythmias
3. Acute bleeding (bronchial bleeding,)
4. **Multiple fractures or trauma** (eg, unstable fractures of femur, pelvis, face)
5. **Spinal instability** (trauma, RA)
6. Pregnancy
7. Raised intracranial pressure
8. Tracheal surgery or sternotomy within two weeks

Prone positioning


Relative contraindication

1. Recent DVT treated for <2 days*
2. Anterior chest tube(s) with air leaks*
3. Major abdominal surgery
4. Recent pacemaker*
5. Clinical conditions limiting life expectancy*
6. Severe burns*
7. Lung transplant recipient*
8. Prior use of rescue therapies (NO, ECMO..)

NO

1. One lung ventilation
2. Obesity


Prone positioning case-sharing



- SCLC /c RUL collapse
- (FiO₂ 60%, PEEP 10, P/F 133
=> Cisplatin+VP-16



- Day-7 after Cisplatin+VP-16
- FiO₂ 90%, PEEP 14, P/F ratio 80
- **Prone ventilation**



- Day-12 after Cisplatin+VP-16
- Supine ventilation
- FiO₂ 50%, PEEP 10, P/F ratio 180


Prone positioning in obese patients

1. Obesity is **NOT generally** considered a contraindication.
2. In PROSEVA trial, the **median body mass index was 28**, ranging from 21 to 36.
3. However, turning patients with **massive obesity** may pose more **procedural challenges**

PRONE POSITIONING OF ARDS PATIENTS WITH OBESITY

MECHANISM OF ACTION

- Recruitment of more tissue in the dorsal region than can be derecruited in ventral regions
- Lung inflation is more homogeneously distributed along the dorsoventral axis of the lung with a decrease in ventilation perfusion inequalities



CLINICAL EFFECTS

- Allows improvement in PaO₂/FIO₂ ratio
- Feasible and safe without increased complications compared to patients without obesity when performed by a trained team
- May help to reduce mortality in ARDS

CAUTION

- Careful abdominal positioning to avoid increased intra-abdominal pressure and organ compression
- Use reverse Trendelenburg position if possible



Prone positioning: complication

- Nerve compression (eg, **brachial plexus injury**)
- Venous stasis (eg, facial edema)
- Dislodging endotracheal tube
- Pressure sores (eg, facial)
- Dislodging vascular catheters or drainage tubes
- Retinal damage
- Vomiting
- Transient arrhythmias

Checklist of prone positioning

P 7 personnel

Prepare

- 1 slide sheet
- 6 pillows
- 1 bedsheet
- Red bungs
- Eye tape & pads
- 5 ECG dots
- Tube tie
- 1 spigot
- Head jelly

Plan

- Sedated + paralysed?
- Eyes taped closed?
- Anchorfast removed + tube tied?
- NG feed stopped and disconnected?
- CVP transducer disconnected?
- Urinary catheter disconnected and spigoted?
- Removed unnecessary infusions?
- Remove ECG dots and leads?
- Disconnect BP cuff / BIS / Temp cables
- Disconnect and spigot arterial line

Proned Patient

- Team leader?
- Team know movements?
- Turn direction?
- Number of movements?

Perform

- Count in and go!
- Check ventilation
- Reconnect all monitoring once complete

Protect

- Check all pressure areas
- Ensure no trapped cables
- Rotate head every 2h / ensure raised arm swapped frequently

Perfect

Pillows

- Pillows central?
- Unimpeded abdominal expansion?
- Toes off bed?

Head & Tubes

- ET tube / NG kink free & position OK?
- Patient's head on jelly / ring?
- Eyes / nose free and no pressure?
- Ventilation OK?

Catheter

- Reconnect - running?

Arms

- Pressure points
- No over extension

CRITICALCARE NORTHAMPTON.COM
REVIEWING CRITICAL CARE, JOURNALS & FORUMS

@wilkinsonjonny

Modular Table System (MTS)



Positioning



PRONE



SUPINE




LATERAL



Prone positioning in 2020[COVID-19 era]

Prone position in ARDS patients: why, when, how and for whom

Gas/Tissue ratio




Open lung mass

Recruitability

38.7 +/- 1.3

56.9 +/- 5




Claude Guérin et al. PMID: 33169218
Intensive Care Med. 2020 Nov 10 : 1–12.

Prone position in ARDS patients: why, when, how and for whom

Supine Position before proning


PaO ₂ /FiO ₂ (mmHg)	PaCO ₂ (mmHg)	P _{plat} (cmH ₂ O)	DrivingP (cmH ₂ O)
74	54	27	21



Proning for 18 hours

Supine position after 18 hours of proning

PaO ₂ /FiO ₂ (mmHg)	PaCO ₂ (mmHg)	P _{plat} (cmH ₂ O)	DrivingP (cmH ₂ O)
115	50	25	19



*Claude Guérin et al. PMID: 33169218
Intensive Care Med. 2020 Nov 10 : 1–12.*

Prone position in ARDS patients: why, when, how and for whom

Unanswered questions




- **Underutilized** of prone ventilation
(improved in COVID-19, **76%** of 735 COVID-19 ARDS in Spain)
- **Optimal duration** is not definitely determined
- How ventilator settings (**PEEP/FiO2**) should be adjusted in prone position is an unanswered issue.
- **Awaken prone** position in non-intubated patients



Claude Guérin et al. PMID: 33169218
Intensive Care Med. 2020 Nov 10 : 1–12.

Optimal PEEP in ARDS




Effect of positive end-expiratory pressure on porcine right ventricle function assessed by speckle tracking echocardiography



Intracardiac echocardiography (ICE), pulmonary artery and arterial catheters



Optimal PEEP Guided by Esophageal Balloon Manometry



Optimal PEEP in prone position?

- 參照PEEP table，是否一定要higher PEEP 目前無定論
- Obesity/腹壓高須考慮higher PEEP

Lower PEEP/higher FiO₂

FiO ₂	0.3	0.4	0.4	0.5	0.5	0.6	0.7	0.7
PEEP	5	5	8	8	10	10	10	12

FiO ₂	0.7	0.8	0.9	0.9	0.9	1.0
PEEP	14	14	14	16	18	18-24

Higher PEEP/lower FiO₂




FiO ₂	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.5
PEEP	5	8	10	12	14	14	16	16

FiO ₂	0.5	0.5-0.8	0.8	0.9	1.0	1.0
PEEP	18	20	22	22	22	24



Optimal FiO₂ in ARDS

Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome



Mesenteric ischemia →

Arrhythmia →


Variable	Conservative Oxygen (N=99)		Liberal Oxygen (N=102)	
	no./total no.	% (95% CI)	no./total no.	% (95% CI)
Mesenteric ischemia	5/99	5.1 (1.7-11.4)	0/102	
Cardiac adverse events				
Arrhythmia	23/99	23.2 (14.9-31.6)	16/102	15.7 (8.6-22.7)
New-onset atrial fibrillation	21/99	21.2 (13.2-29.3)	13/102	12.7 (6.3-19.2)
Events leading to treatment	23/99	23.2 (14.9-31.6)	14/102	13.7 (7.0-20.4)

A relatively high oxygenation (SaO₂ 96%) might be feasible in those with risk for mesenteric ischemia or arrhythmia.

Is **NMBAs** **always** required in ARDS
without and with prone positioning?

Neuromuscular blockers in early acute respiratory distress syndrome

ACURASYS



- 2 days of Cisatracurium

- Patients with severe ARDS. (P/F ratio < 150)

- The impact of VILI appeared to be prominent after day-15


(Baseline mortality: 45%)

Papazian L. et al. *ACURASYS Study Investigators.*
N Engl J Med. 2010 Sep 16;363(12):1107-16.



Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans


- **Background:** Diaphragm inactivity post mechanical ventilation for **18 hours in animals.**
- **Study-design:**
 - ✓ Case: Costal diaphragms of **14 brain-dead organ donors. (MV: 18-69 hours)**
 - ✓ Control: **Intraoperative diaphragm-biopsy** of 8 patients. (MV: 2-3 hours).



Active caspase-3 (protein degradation)



Atrogin-1/MuRF-1 (ubiquitin ligases)




Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome


ROSE trial

lightly sedated (RASS 0 to -1)

The ROSE Trial



1006 Patients within 48 hr of diagnosis of moderate-to-severe ARDS

Intervention Group	Control Group
	
<ul style="list-style-type: none">• Deep sedation• 48 hr of continuous cisatracurium	<ul style="list-style-type: none">• Usual care• Light sedation• No neuromuscular blockade
Same ventilator care	


PEEP of ≥ 8 cm

1,408 → early stopped

PETAL Clinical Trials Network. PMID: 31112383
Prevention and Early Treatment of Acute Lung Injury (PETAL)
N Engl J Med. 2019 May 23;380(21):1997-2008.

Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome

ROSE trial



PETAL Clinical Trials Network. PMID: 31112383
Prevention and Early Treatment of Acute Lung Injury (PETAL)
N Engl J Med. 2019 May 23;380(21):1997-2008.

Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome

ROSE trial

1,408 → 1006 **early stopped**

Adverse Events

ICU-acquired weakness

At Day 7: 41.0% vs. 31.3% (Difference -9.7, 95% CI -21.5 to 2.1)

At Day 28: 46.8% vs. 27.5% (Difference -19.4, 95% CI -38.2 to -0.6)

Serious adverse events

35 events vs. 22 events (P=0.09)

Barotrauma: 4.0% vs. 6.3% (P=0.12)

Serious adverse cardiovascular events: 14 events vs. 4 events (P = 0.02)

System/disorder	Event	Severity	Intervention	Control
Blood/lymphatic	Methemoglobinemia	Serious	2	0
Cardiac	Complete atrioventricular block	Serious	1	0
	Atrial fibrillation (paroxysmal)	Non-Serious	1	0
	Atrial fibrillation w/ rapid vent response	Serious	1	0
	Bradycardia	Serious	1	0
	Cardiac arrest	Non-Serious	1	0
	Cardiac arrest	Serious	6	2
	Cardiac arrhythmia (NOS)	Non-Serious	0	2
	3rd degree atrioventricular block	Serious	1	0
	Myocardial infarction	Serious	0	1
	Serious prolonged bradycardia	Serious	1	1
	Tachycardia	Non-Serious	1	0
	Supraventricular tachycardia	Non-Serious	1	0
	Torsades De Pointe	Serious	1	0
	Vasovagal reaction	Serious	1	0
	Ventricular tachycardia	Non-Serious	0	1
	Ventricular tachycardia	Serious	2	0

Cardiac arrest



PETAL Clinical Trials Network. PMID: 31112383
 Prevention and Early Treatment of Acute Lung Injury (PETAL)
 N Engl J Med. 2019 May 23;380(21):1997-2008.

Is **NMBAs** **always** required in ARDS without
and with prone positioning?

Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome

ROSE trial

lightly sedated (RASS 0 to -1)



- **Prone positioning** was used in **15.8%** of patients (**159/1006**), with **similar use in the two groups**.
- **Most (56%, 42/75 patients)** of patients who underwent prone positioning in the control group

did not receive concomitant NMBAs

PETAL Clinical Trials Network. PMID: 31112383
N Engl J Med. 2019 May 23;380(21):1997-2008.

Surviving Sepsis Campaign Guidelines 2021

For adults with sepsis induced moderate-severe ARDS, we suggest using **intermittent** NMBA boluses, over NMBA continuous infusion.

Quality of evidence: Moderate

Ventilation

Weak

Neuro Muscular Blockade

Intermittent NMBA boluses, over NMBA **continuous** infusion

Is NMBA always required in ARDS
without and with prone positioning?



Real-world use of **NMBAs** among
patients with ARDS **in Taiwan**


Usage of sedative agents and neuromuscular blockade of subjects with influenza-related ARDS during 2016 influenza epidemic in Taiwan

Administration-day of sedative agents and neuromuscular blockade in influenza-related ARDS

	All	Severe-ARDS	Moderate-ARDS	Mild-ARDS
	N=216	N=135	N=60	N=21
Sedative agent (days)	10.6±9.6	11.7±9.8	9.6±10.1	6.5±4.8
Neuromuscular blockade (days)	6.2±5.5	7.4±5.4	5±5.4	2±3.6

Taiwan Severe Influenza Research Consortium (TSIRC) investigators.

Administered-day of NMBA in subjects with influenza-related **severe ARDS** by participating **hospital**



Taiwan Severe Influenza Research Consortium (TSIRC) investigators.

Prone position in ARDS patients: why, when, how and for whom

Unanswered questions

1. **Underutilized** of prone ventilation.
2. **Optimal duration** is not definitely determined.
3. **Ventilator settings** (PEEP/FiO₂) in prone should be addressed.
4. **NMBAs** may not be always required .
5. **Awaken prone position in non-intubated patients**



Claude Guérin et al. PMID: 33169218
Intensive Care Med. 2020 Nov 10 : 1–12.

Awake Proning **without ventilator**

COVID-19: Awake Proning



 **REBEL
COVID-19**



Anand Swaminathan et al.

<https://rebelem.com/covid-19-awake-proning/>

Intubation rate of patients with hypoxia due to COVID-19 treated with **awake proning**: A meta-analysis

- 16 studies with 364 patients
- The intubation rate was 28% (95% CI 20%-38%, I² = 63%).
- The mortality rate among patients who underwent awake PP was 14% (95% CI 7.4%-24.4%).

*Stephanie Cardona et al. PMID: 33550104
Am J Emerg Med . 2021 Jan 27;43:88-96*

Intubation rate of patients with hypoxia due to COVID-19 treated with **awake proning**: A meta-analysis

16 studies with 364 patients → High heterogeneity

Delta ROX index might potentially a predictor for intubation

Table 3B

Results from meta-regression measuring the associations between continuous variables and outcome of any intubation during hospital stay

Moderator variables	Number of studies	Correlation coefficient	95% CI	P value	R ²	I ²
Age - years	17	0.06	-0.02, 0.14	0.14	0	66%
Percent of male patients	17	1.7	-1.3, 5.01	0.3	0	65%
BMI	6	0.15	-0.13, 0.43	0.29	0.1	81%
Initial P/F ratio ^a	12	0	-0.01, -0.85	0.4	0	66%
Delta P/F ratio ^a	12	0.01	-0.01, 0.03	0.36		
Initial ROX index ^b	11	-0.07			0.51	67%
Delta ROX index^b	9	0.1	-0.01, 0.2	0.06		
Proning duration per day (hours)	8	0.04	-0.19, 0.26	0.76	0	1%
Total duration of proning (hours)	9	-0.04	-0.09, 0.01	0.12	0.47	31%

^{a,b}Multivariable meta-regressions included both continuous variables.

95% CI, 95% confidence interval; BMI, body mass index; Delta, change between initial and repeat values of ROX index or P/F ratio; P/F ratio, PaO₂ (partial pressure of oxygen)/FiO₂ (fraction of inspired oxygen) ratio; ROX index, respiratory oxygen index.

*Stephanie Cardona et al. PMID: 33550104
Am J Emerg Med . 2021 Jan 27;43:88-96*

High Flow Nasal Cannula

- HFNC使用之後，何時決定換BiPAP或插管

→ ROX index < 4.88

$$\text{ROX Index} = (\text{SpO}_2/\text{FiO}_2)/\text{RR}$$

→ ROX index不考慮PaCO₂, pH, HCO₃

(HFNC主要提升氧合功能，RR變快就表示只靠提升氧合已經撐不住)

→ ROX 4.88 → FiO₂ 60%, SpO₂ 94%, RR:32


An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy

pneumonia with acute respiratory failure

ROX index → $[SpO_2/FIO_2] / RR$

2h after HFNC

A




Number at risk

ROX ≥ 4.88	105	40	11	8	1
ROX < 4.88	74	26	11	4	1

6h after HFNC

B



Number at risk

ROX ≥ 4.88	127	53	17	12	3
ROX < 4.88	49	16	8	1	0


Roca O et al. PMID: 30576221

Am J Respir Crit Care Med. 2019 Jun 1;199(11):1368-1376.


ROX Index to Guide Management of COVID-19 Pneumonia

ROX index \rightarrow $[\text{SpO}_2/\text{FIO}_2] / \text{RR}$

ROX 4.88 at **0-hr**



ROX 4.88 at **2-hr**




*Douglas L Fink et al. PMID: 33636094
Ann Am Thorac Soc. 2021 Feb 26.*

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial


N=1126

Treatment failure (intubation or death).




	0	7	14	21	28
Number at risk (number censored)					
Standard care	557 (0)	345 (0)	310 (0)	299 (0)	298 (298)
Awake prone positioning	564 (0)	405 (0)	358 (0)	344 (0)	341 (341)

Intubation




Death




Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial


SpO₂/FiO₂



Respiratory rate



ROX index




Conclusions

1. Awake prone positioning of patients with hypoxaemic respiratory failure due to [COVID-19 reduces the incidence of treatment failure and the need for intubation](#) without any signal of harm.
2. These results [support routine awake prone positioning](#) of patients with COVID-19 who require support with high-flow nasal cannula.

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial

The optimal/feasible duration of awake prone positioning remains unclear.



Stephan Ehrmann et al. *Awake Prone Positioning Meta-Trial Group*
Lancet Respir Med. 2021 Dec;9(12):1387-1395. PMID: 34425070

Outline

1. Prone ventilation till 2013 [PROSEVA]
2. Prone ventilation evidence ~2014-2019
[LUNG-SAFE, TSIRC, APRONET]
3. Prone positioning in COVID-19 era
4. Prone ventilation on ECMO

Prone on ECMO

- Effect of prone positioning on survival in adult patients receiving venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis.

*Papazian L et al. PMID: 35037993
Intensive Care Med. 2022 Mar;48(3):270-280.*

- Prone positioning during venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a pooled individual patient data analysis.


*Giani M et al. (EuroPronECMO Investigators.)
Crit Care. 2022 Jan 6;26(1):8. PMID: 34986895*

- Beneficial Effect of Prone Positioning During Venovenous Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019.


*Zaaqoq AM et al. COVID-19 Critical Care Consortium (COVID Critical).
Crit Care Med. 2022 Feb 1;50(2):275-285. PMID: 34582415*

Prone positioning during venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a pooled individual patient data analysis. [n=889]

Matched groups of patients



Patients at risk, n	0	10	20	30	40	50	60
Supine group	227	177	120	84	56	42	34
Prone group	227	213	166	166	77	52	40



Conclusions:

In a large population of ARDS patients receiving venovenous extracorporeal support, the use of prone positioning during ECMO was **not** significantly associated with reduced ICU mortality.

Take home message

1. Prone positioning **improves mortality** in ARDS (P/F <150) under **concurrent protective ventilation strategy**.
2. Prone positioning **is relatively underutilized** and increasingly applied in **COVID-19 era**.
3. Optimal **duration, PEEP, FiO₂**, and **use of NMBAs** remains to be elaborated.
4. **Awake prone** position is feasible and may be standard of care among patients with COVID and require HFNC in the near future.
5. Prone position might be feasible in ARDS patients receiving ECMO.
6. More **Taiwanese data** are urgently needed.



臺中榮民總醫院
Taichung Veterans General Hospital



中榮官網



中榮FB

感謝您的聆聽！

Thank you !



